The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada.
Patricia A. Tang
No relevant relationships to disclose
Annette E. Hay
No relevant relationships to disclose
Christopher J. O'Callaghan
No relevant relationships to disclose
Nicole Mittmann
No relevant relationships to disclose
Carole Chambers
No relevant relationships to disclose
Joseph L Pater
No relevant relationships to disclose
Natasha B. Leighl
No relevant relationships to disclose